Rejuvenate Biomed — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rejuvenate Biomed is an AI-enabled, clinical-stage biotech based in Leuven, Belgium, focused on developing prescription drugs for healthy aging. The company is advancing a pipeline led by RJx-01, currently in a Phase 2 trial for COPD-related sarcopenia, and utilizes AI-driven drug repurposing tools developed in partnership with SAS. As a private, pre-revenue company, it has established key collaborations with academic and research institutions like the NIHR Leicester BRC and Wellcome Leap to validate its therapeutic approach in age-related diseases.

Healthy AgingSarcopeniaCOPDAge-related Diseases

Technology Platform

AI-enabled, disease-agnostic drug repurposing and discovery platform developed in partnership with SAS.

Opportunities

The global aging population creates a massive, growing market for therapies that promote healthy aging and treat conditions like sarcopenia, where there are few approved drugs.

The AI-driven repurposing strategy offers a faster, lower-cost development pathway with a higher probability of clinical success due to known compound safety.

Risk Factors

High clinical risk associated with the ongoing Phase 2 trial for its lead asset.

The company is pre-revenue and dependent on external financing in a volatile biotech funding environment.

The geroscience field is complex, and regulatory pathways for aging-related indications are not fully established.

Competitive Landscape

The field of geroscience and sarcopenia treatment is becoming increasingly competitive, with numerous biotech startups and large pharma companies exploring similar mechanisms. However, Rejuvenate's specific focus on acute exacerbation of COPD and its AI-powered repurposing platform may provide a differentiated niche.

More companies in Small Molecule Drugs →More companies in Belgium →